Valvular Heart Disease and “Nonvalvular Atrial Fibrillation” Coumadin or a Novel Oral Anticoagulant Variables to Consider

Cardiology: Open Access
doi 10.33140/coa/03/01/00003
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Opast Group LLC

Related search

How to Choose Appropriate Direct Oral Anticoagulant for Patient With Nonvalvular Atrial Fibrillation

Annals of Hematology
MedicineHematology
2015English

Suboptimal Oral Anticoagulant Treatment Among Chinese Non-Valvular Atrial Fibrillation Patients: The Nanchang Atrial Fibrillation Project

Archives of Medical Science
Medicine
2016English

Modern Approaches to Anticoagulant Therapy During Catheter Ablation Treatment of Non-Valvular Atrial Fibrillation

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2014English

PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER Study)

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2015English

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2018English

Novel Anticoagulants for Thromboembolic Complications Prevention in Nonvalvular Atrial Fibrillation

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Risk Stratification of Nonvalvular Atrial Fibrillation

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2013English

Underuse of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation in Italy

Internal and Emergency Medicine
Internal MedicineEmergency Medicine
2007English

Effect and Risk of Novel Oral Anticoagulants Versus Warfarin in Patients With Non-Valvular Atrial Fibrillation

Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy